PharmaResearch (214450) stock
KOSDAQ · Health Care Equipment & Supplies
As of the Nov 16 regular-session close (Korea)
Events and reference metrics · 1
- Market cap
- KRW 2.7 trillion
- As of Nov 16, 2026
- P/E
- 16.05x
- Trailing twelve months
- P/B
- 3.84x
- Latest reported equity
- P/S
- 4.18x
- Trailing twelve months
- ROE
- 23.9%
- Trailing twelve months
- Dividend yield
- 1.44%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
- Market cap
- KRW 2.7 trillion
- As of Nov 16, 2026
- P/E
- 16.05x
- Trailing twelve months
- P/B
- 3.84x
- Latest reported equity
- P/S
- 4.18x
- Trailing twelve months
- ROE
- 23.9%
- Trailing twelve months
- Dividend yield
- 1.44%
- Dividends observed in the last year
Multiples use the price as of Nov 16, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
16.05x
P/B
3.84x
P/S
4.18x
Earnings and dividend metrics▾
Earnings
EPS
KRW 16,042
Earnings per share
BPS
KRW 67,076
Book value per share
ROE
23.9%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned KRW 16,042 per share.
- BPS — net assets divided by the number of shares. Each share is backed by KRW 67,076 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 23.9%.
Dividends
1 observed in the last year · Record dates: Dec
Yield
1.44%
Dividend per share
KRW 3,700
Payout ratio
25.9%
Consecutive years
4+ yrs
Yield uses dividends observed over the last year (by record date) · Dividend per share and payout ratio are for fiscal 2025.
- Dividend yield — dividends divided by the share price (or market cap). It falls when the price rises.
- Dividend per share — the fiscal-year dividend per share. For one hundred shares that is about KRW 370,000 before tax.
- Payout ratio — 25.9% of earnings was paid out as dividends.
- Consecutive years — dividends were paid every year for more than 4 years. That does not mean they will continue.
Reference only · not a promise of future dividends
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from DART financial filings: net income attributable to owners of the parent and revenue are summed over the latest four quarters, equity is the latest reported equity, and prices are KRX closing prices.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Earnings
Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| Q2 2026Consolidated · Filed Aug 14, 2026 | KRW 178.7 billion | KRW 66.5 billion | KRW 56.2 billion | +27.1% |
| Q1 2026Consolidated · Filed May 15, 2026 | KRW 146.1 billion | KRW 57.3 billion | KRW 48.7 billion | +25.0% |
| Q4 2025Consolidated · Filed Mar 19, 2026 | KRW 143.3 billion | KRW 51.9 billion | KRW 39.3 billion | — |
| Q3 2025Consolidated · Filed Nov 14, 2025 | KRW 135.4 billion | KRW 61.9 billion | KRW 50.9 billion | +51.8% |
| Q2 2025Consolidated · Filed Aug 14, 2025 | KRW 140.6 billion | KRW 55.9 billion | KRW 42 billion | +69.2% |
| Q1 2025Consolidated · Filed May 21, 2025 | KRW 116.9 billion | KRW 44.7 billion | KRW 36 billion | +56.5% |
| Period | Revenue | Operating profit | Net income | Revenue YoY |
|---|---|---|---|---|
| FY2025Consolidated · Filed Mar 19, 2026 | KRW 536.3 billion | KRW 214.4 billion | KRW 168.3 billion | — |
| FY2024Consolidated · Filed Mar 17, 2025 | KRW 350.1 billion | KRW 126.1 billion | KRW 88.9 billion | — |
- Q2 2026 is computed as H1 2026 minus Q1 2026.
- Q4 2025 is computed as FY2025 minus 9M 2025.
- Q3 2025 is computed as 9M 2025 minus H1 2025.
- Q2 2025 is computed as H1 2025 minus Q1 2025.
Short selling and securities lending
Short sales as a share of trading value, the reported short position and the securities lending balance.
- Short-sale share
- 4.12%
- Of trading value on Nov 13, 2026
- Short-sale value
- KRW 1.06 billion
- Previous 20-day average 6.47%
- Net short position
- 26,619 shares
- As of Nov 11, 2026 · reported with a two-trading-day lag
- Lending balance
- 872,915 shares
- As of Nov 13, 2026 · 8.40% of listed shares
| Date | Share | Value |
|---|---|---|
| Nov 13, 2026 | 4.12% | KRW 1.06 billion |
| Nov 12, 2026 | 10.82% | KRW 2.67 billion |
| Nov 11, 2026 | 2.89% | KRW 810 million |
| Nov 10, 2026 | 6.02% | KRW 1.58 billion |
| Nov 9, 2026 | 12.80% | KRW 3.49 billion |
| Nov 6, 2026 | 10.08% | KRW 6.04 billion |
| Nov 5, 2026 | 6.34% | KRW 1.58 billion |
| Nov 4, 2026 | 5.20% | KRW 1.02 billion |
| Nov 3, 2026 | 6.77% | KRW 730 million |
| Nov 2, 2026 | 6.53% | KRW 1.42 billion |
The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.
Filings
Major filings received by DART, Korea’s regulatory filing system.
- Report on Major Holdings of Shares (General Form)Nov 12, 2026 · Major Holding ReportEnglish
- Report on Specified Securities Held by Executives and Major ShareholdersNov 12, 2026 · Insider Ownership ReportEnglish
- Preliminary Consolidated Operating Results (Fair Disclosure)Nov 6, 2026 · Preliminary EarningsEnglish
- Report on Major Holdings of Shares (Short Form)Oct 2, 2026 · Major Holding ReportEnglish
- Preliminary Consolidated Operating Results (Fair Disclosure)(Korean)Aug 7, 2026 · Preliminary Earnings
- Preliminary Consolidated Operating Results (Fair Disclosure)(Korean)May 8, 2026 · Preliminary Earnings
- Report on Specified Securities Held by Executives and Major Shareholders(Korean)Apr 9, 2026 · Insider Ownership Report
- Corporate Value-up Plan (Voluntary)(Korean)Mar 30, 2026 · Corporate Value-up Plan
Filings with a published English version open in English; the rest link to the Korean original.
PharmaResearch (214450) stock information
KOSDAQ
PharmaResearch (214450) is listed on KOSDAQ. Its market capitalization is about KRW 2.7 trillion. On trailing-twelve-month earnings the P/E ratio is 16.05, and the P/B ratio is 3.84. Return on equity is 23.9%. These figures are computed in-house from official filings and are reference information only.
PharmaResearch — frequently asked questions
- What is the P/E ratio of PharmaResearch (214450)?
- On a trailing-twelve-month basis, 214450 trades at a P/E ratio of 16.05. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of PharmaResearch?
- 214450 has a market capitalization of about KRW 2.7 trillion. The figure moves with the share price and is refreshed each trading day.
- Does PharmaResearch pay a dividend?
- 214450 has a dividend yield of about 1.44%, based on disclosed payment history. Dividend policy can change; this is reference information only.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.